73,889 Shares in Stryker Corporation $SYK Bought by Dearborn Partners LLC

Dearborn Partners LLC purchased a new position in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 73,889 shares of the medical technology company’s stock, valued at approximately $24,279,000. Stryker makes up about 1.3% of Dearborn Partners LLC’s portfolio, making the stock its 29th biggest holding.

A number of other hedge funds and other institutional investors also recently modified their holdings of SYK. Gables Capital Management Inc. acquired a new position in shares of Stryker during the 2nd quarter worth about $25,000. Kilter Group LLC acquired a new stake in Stryker in the 2nd quarter valued at about $25,000. Godfrey Financial Associates Inc. bought a new position in Stryker during the fourth quarter worth about $26,000. Sankala Group LLC bought a new position in Stryker during the fourth quarter worth about $26,000. Finally, Compass Financial Management LLC acquired a new position in Stryker during the second quarter worth approximately $27,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In related news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This trade represents a 2.17% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 355,370 shares of company stock valued at $119,447,201. 4.60% of the stock is owned by company insiders.

Stryker Trading Down 0.5%

Shares of NYSE:SYK opened at $327.80 on Tuesday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The stock has a market cap of $125.73 billion, a PE ratio of 33.97, a P/E/G ratio of 2.10 and a beta of 0.76. The business has a 50 day moving average of $327.39 and a 200-day moving average of $332.16. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Analyst Upgrades and Downgrades

SYK has been the topic of several research analyst reports. BMO Capital Markets began coverage on Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective on the stock. Piper Sandler reduced their target price on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Raymond James Financial set a $370.00 target price on Stryker in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a research note on Friday, May 1st. Finally, JPMorgan Chase & Co. cut their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.